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Summary
Epidemiologic studies clearly document the public health burden of sudden unexpected death in 
epilepsy (SUDEP). Clinical and experimental studies have uncovered dynamic cardiorespiratory 
dysfunction, both interictally and at the time of sudden death due to epilepsy. Genetic analyses in 
humans and in model systems have facilitated our current molecular understanding of SUDEP. 
Many discoveries have been informed by progress in the field of sudden cardiac death and sudden 
infant death syndrome. It is becoming apparent that SUDEP genomic complexity parallels that of 
sudden cardiac death, and that there is a pauci1ty of analytically useful postmortem material. 
Because many challenges remain, future progress in SUDEP research, molecular diagnostics, and 
prevention rests in international, collaborative, and transdisciplinary dialogue in human and 
experimental translational research of sudden death.
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Individual risk prediction remains challenging: A particular concern is that patients with 
relatively well-controlled epilepsy, including those with infrequent seizures, remain at risk 
for sudden death.1 The focus of this article is to explore the role of genetic factors in sudden 
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unexpected death in epilepsy (SUDEP). In this, we draw on research in sudden cardiac death 
(SCD) and sudden infant death syndrome (SIDS).
Lessons from Research on the Genetics of Sudden Cardiac Death
The annual rate of SCD is estimated at 50–100,000 in the United Kingdom and 300,000 in 
the United States.2 Sudden arrhythmic death syndrome (SADS) refers to SCDs that remain 
unexplained despite a comprehensive autopsy and toxicology, and are presumed to be due to 
genetic causes such as familial long-QT syndrome (LQTS) and Brugada syndrome (BrS).3,4 
This accounts for 4% of SCDs in patients younger than 64 years of age and up to 40% in 
patients younger than 35.5 Much is known about these monogenic conditions and their 
presentation.6 Yet, it is increasingly evident that oligogenicity (interactive influence of a 
small number of genes) and common genetic variation may modify pathogenesis of these 
disorders and the risk of SCD.7–10
Evidence for a genetic basis for SCD in the young
Structural cardiac disease accounts for approximately 60% of sudden death in that occurs in 
the young before 35 years of age.11 In the presence of familial disease, candidate gene 
testing will identify mutations in ~60% hypertrophic, 25% dilated, and 40% arrhythmogenic 
right ventricular cardiomyopathies.12 Diagnostic yield in patients with SADS rests in the 
profiling of genes responsible for LQTS, BrS, and catecholaminergic polymorphic 
ventricular tachycardia (CPVT): cardiac potassium channel alpha and beta subunits KCNQ1, 
KCNH2, KCNE1, and KCNE2; the cardiac sodium channel alpha subunit SCN5A; and the 
sarcoplasmic reticulum calcium release channel, the Ryanodine receptor (RyR2),5,13 
respectively. The mutation prevalence in these genes is estimated at around 15–20%.5,14 
Careful cardiologic evaluation of the family can increase the detection rate from 22% to 
53%.15,16 It is now known that those at greatest risk may carry multiple genetic variants.12 
Multiple mutation carriers represent approximately 7% of LQTS probands, and they present 
with more severe disease.17
It has been established that even acquired arrhythmic risk is genetically influenced; in the 
Paris prospective study, the risk of SCD in middle-aged men was doubled in the presence of 
a parental SCD history.18 Investigation focused on common nonsynonymous single 
nucleotide polymorphisms (SNPs) found association of the SCN5A-S1103Y with an 
eightfold increased risk of SCD due to any cause in African Americans.19 Moreover, the 
S1103Y allele carriers had 8.4 (2.1–28.6) relative risk (RR) for SADS compared to 
noncardiac death and S1103Y homozygosity in infancy carried an odds ratio (OR) of 24.4 in 
SIDS risk.20,21
Evidence for a genetic basis to coronary SCD: Synonymous common genetic variation
In a large Dutch cohort, cardiac arrest due to ventricular fibrillation (VF) following a first 
acute ST-elevation myocardial infarction (STEMI) was threefold more common in those 
with a family history for SCD.22 Genome-wide association studies (GWAS) of 972 STEMI 
cases, of which 515 had a cardiac arrest, associated the risk of VF with the common 
polymorphism rs2824292 next to a coxsackievirus v receptor gene CXADR,10 which can 
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increased arrhythmogenicity in the setting of ischemia through altered cardiac conduction.23 
GWAS in a 1,268 SCDs identified and replicated the association of the rs4665058 common 
variant near the BAZ2B gene (bromodomain adjacent zinc finger domain 2B),9 with as yet 
unclear functional significance. GWAS of electrocardiographic phenotypes linked to SCD 
risk found the strongest association with the NOS1AP (nitric oxide synthase 1 adaptor 
protein) gene24 that has been linked to the risk of SCD in the general population as well as 
in congenital LQTS.25,26
Repolarization reserve: An example of genetic susceptibility to SCD
Acquired LQTS is an idiosyncratic and rare adverse drug reaction that causes both QT 
prolongation and torsades de pointes (TdP), the polymorphic ventricular tachycardia 
characteristic of congenital LQTS. It is an important issue in drug safety and development. 
A rare LQTS genetic variant is detected in approximately10% of cases.27 Much of the risk 
associated with S1103Y in African Americans in the early study by Splawski et al.19 was 
related to medications known to prolong the QT interval. S1103Y prolongs late sodium 
current that in turn delays cardiac repolarization. KCNE1-D85N, is another example of a 
common SNP associated with an eightfold increased risk of drug-induced TdP in people 
taking QT-prolonging drugs.28 Noncoding SNPs of the NOS1AP gene were also linked to 
the risk of drug-induced TdP in patients taking amiodarone, a commonly used 
antiarrhythmic agent.8 These data support the hypothesis of the “repolarization reserve,” a 
physiologic redundancy of capacity to repolarize the myocardium. Overt congenital LQTS is 
caused by rare functionally severe mutations while some rare or common genetic variations 
underlie a concealed genetic reduction of repolarization reserve, which prolongs the QT 
interval to a minimal extent.29 The risk of “acquired” LQTS increases with exposure to 
insults, such as QT-prolonging medications, hypokalemia, or subarachnoid hemorrhage, 
particularly as such factors may be additive. In addition, women tend to have longer QT 
intervals and are thus at higher risk for either congenital or acquired LQTS.
Implications for future research
Genetic testing due to SCD concern is relevant not only in suspected cardiomyopathy or 
arrhythmias but also in people with other disorders. The potential overlap with genetic risk 
in SUDEP remains to be explored. For example, the seizure-induced bradycardia, acidosis, 
and autonomic dysfunction may represent an insult to repolarization reserve. However, 
misdiagnosis of epilepsy also needs to be considered. Cerebral anoxia secondary to a cardiac 
arrhythmia may be responsible for the seizure phenotype, particularly in the young adult 
who dies after one, or only a few, seizures, or has exertion-related seizures. This clinical 
presentation of an arrhythmia syndrome must not be forgotten given the implications of risk 
to the family. Although only relevant to patients with some genetic epilepsies, there is also 
the possibility that the same genetic abnormality predisposing to epilepsy predisposes to 
SCD as discussed below. Finally, although molecular autopsy has started to be applied in 
SUDEP cases on a research basis, family assessment for SCD genetic risk may also be a 
good avenue to explore.
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The Genetic Spectrum of SUDEP
The panel of candidate SUDEP genes has been growing rapidly, and discoveries have been 
facilitated by progress in the field of SCD and SIDS, and by translational research in 
sophisticated animal models.
Arrhythmia genes
The discovery of cardiac voltage-gated sodium channel SCN5A in brain limbic regions 
provided the first link between genetically predisposed cardiac arrhythmias and epilepsy.30 
Subsequent clinical case studies supported the concept of a combined neurocardiac 
phenotype triggered by mutations in ion channels dually expressed in the brain and in the 
heart.31,32 This was followed by the report of epilepsy, cardiac arrhythmias, and SUDEP in 
transgenic mice carrying the human knock-in mutations in the most common LQT gene, the 
potassium channel KCNQ1.33 The observed model SUDEP event mirrored a previously 
described human case report,34 and the study uncovered some of the candidate networks and 
mechanisms involved in the lethal epilepsy outcome. Consequently, a seizure phenotype was 
identified in 28% of cases with confirmed LQTS caused by pathogenic variants in the 
KCNH2, KCNQ1, and SCN5A genes,35–37 and variants of suspected functional significance 
were uncovered in 10% of 48 SUDEP cases.38 Yet, the molecular underpinnings of 
neurocardiac interactions extend beyond the LQT gene family; a catecholaminergic 
polymorphic ventricular tachycardia (CPVT) is a dysrhythmia presenting with stress-
induced syncope39 and a high 30–50% mortality rate before the age of 3039 due to a defect 
in the ryanodine receptor (RYR2).40 The mouse model carrying the human mutation 
R2474S displayed exercise-induced ventricular arrhythmia and early onset spontaneous 
convulsive seizures, and lethal arrhythmia triggered sudden death.41 The combined 
phenotype of arrhythmias and seizures was also observed in 12 of 24 of Dutch CPVT 
families affected by RYR2 mutations39 and a missense variant RYR2-G4936A was found in 
an 8-year-old SUDEP case with history of epilepsy and recurrent, exercise-induced syncope 
with normal resting electrocardiography (ECG).42 The hyperpolarization-activated cyclic 
nucleotide-gated ion channels HCN1-4 are implicated in epilepsy and cardiac arrhythmias, 
owing to their involvement in the generation of the cation (Na+ and K+)–triggered Ih 
depolarizing current that facilitates action potential and a spontaneous rhythmic activity in 
the neurons and pacemaking cardiomyocytes.43–48 The HCN2-deficient mouse displays 
absence epilepsy and sinus arrhythmia,49 albeit without evidence of a reduced life span. A 
clinically confirmed phenotype of epilepsy and arrhythmia in humans has not yet been 
observed, although HCN coding variants of suspected functional significance were 
uncovered in a mutational screen of 48 SUDEP cases.50 Therefore, the involvement of HCN 
channels in clinically manifest arrhythmia or epilepsy justifies the consideration of this gene 
family in candidate SUDEP genes.
Epilepsy genes
Many ion channel genes regulating the central control of cardiac and respiratory function are 
also expressed within the brain networks thought to underlie epilepsy. For example, the 
voltage-gated potassium channel KCNA1 is expressed in brain and in the vagus nerve. The 
Kcna1 null mice show seizures, cardiac arrhythmias, vagal hyperexcitability, and premature 
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death.51 This channel was also clinically validated in a SUDEP case affected by epileptic 
encephalopathy and suspected cardiac dysrhythmias carrying de novo and novel KCNA1 
intragenic duplication.52 The report of familial SUDEP in a kindred affected by the genetic 
epilepsy syndrome generalized epilepsy with febrile seizures plus (GEFS+) while 
segregating a novel variant in SCN1A gene brought attention to this sodium channel 
subunit,53 a principal gene underlying the Dravet syndrome (DS). Patients with DS face an 
increased risk of premature mortality currently estimated to affect about 4–12% of 
children,54–56 and they seem predisposed to autonomic dysfunction, as evidenced by 
depressed heart rate variability (HRV)57,58 and increased P- and QT-interval dispersion.58 
The Scn1a deficient models mirror the complex human phenotype, exhibiting spontaneous 
seizures, autonomic instability, and seizure-driven vagal activation preceding sudden 
death.59,60 Administration of parasympatholytics reduced the incidence of ictal bradycardia 
and SUDEP in the model.60 A knock-in mouse model carrying the human mutation SCN1A-
R1407X61,62 displayed a 21% premature death rate, spontaneous seizures, and a prolonged 
QT interval due to the increased sodium channel–dependent cardiac current in 
cardiomyocytes.62 Cardiac arrhythmias in this model often preceded apparent convulsive 
seizures, thus indicating that some SCN1A variants might predispose to sudden death 
through neurocardiac or sole cardiac mechanisms.62 There is also experimental evidence that 
mortality risk in DS is influenced by the affected neuronal cell type and regionally specific 
differences in Scn1a brain expression; selective Nav1.1 deficiency in inhibitory γ-
aminobutyric acid (GABA)ergic neurons led to a more severe epileptic phenotype and early 
and frequent sudden death as compared to mice with constitutive Scn1a deficiency.61 Scn1a 
deficiency restricted to forebrain excitatory neurons combined with global Nav1.1 deficiency 
in inhibitory GABAergic neurons mitigated the seizure phenotype and lessened the 
incidence of model SUDEP.61 The discoveries linking KCNA1 and SCN1A to SUDEP 
brought attention to other epilepsy genes. The SCN1B gene encodes a voltage-gated sodium 
channel (VGSC) β subunit critical for proper gating and cell surface expression of the VGSC 
complex.63 SCN1B mutations are linked to GEFS+, temporal lobe epilepsy, as well as 
DS.64–66 The Scn1b null mouse model displays spontaneous seizures, prolonged QT and RR 
intervals, and early mortality.67,68 Spontaneous epilepsy and >30% premature mortality was 
also observed in a mouse deficient in the glutamic acid decarboxylase isoform GAD65.69 
Confirmation of SCN1B and GAD65 in human SUDEP awaits discovery. Comprehensive 
genomic profiling is certain to facilitate the finding of novel molecular candidates as shown 
by the detection of a functionally active de novo variant in the SCN8A channel gene in a 
child affected by epileptic encephalopathy and SUDEP.70–72 SUDEP was also reported in 
children affected by epilepsy due to variants in the KCNQ2 gene.73
Genes involved in respiration and arousal
Animal models74–77 and translational human studies78 have uncovered the critical role of 5-
hydroxytryptamine (5-HT) in respiration and arousal79 and they are discussed in detail 
elsewhere in this supplement. Mice deficient in the 5-HT2c receptor develop epileptic 
seizures and are susceptible to premature death,74 and the genetically engineered Lmx1bf/f/p 
mice depleted of all 5-HT neurons have severe apnea, hypoventilation, diminished 
hypercapnic response, compromised arousal from sleep, and premature mortality.80 There 
are known alterations in expression levels of several 5-HT receptors in the DBA/2 
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audiogenic seizure model with ictally induced respiratory arrest and sudden death.81 These 
discoveries have led to early pharmacologic intervention exploring the possible beneficial 
effect of the widely available serotonin reuptake inhibitors (SSRIs) on SUDEP risk. 
Administration of SSRI in the DBA/1 model ameliorated ictally induced respiratory arrest 
and death and the effect was age dependent.82,83 Clinical observations reflected the animal 
data, as people with epilepsy chronically exposed to SSRIs were less likely to experience 
profound oxygen desaturation with partial, but not secondarily generalized, seizures.78
Complex genetics of human SUDEP
There is growing evidence that variant functional properties along with complex genetic 
interactions influence the phenotypic expressions of cardiac arrhythmias,12,84,85 
epilepsy,52,86,87 and SUDEP.52 Although SCN8A gain-of-function mutations are implicated 
in epileptic encephalopathies and SUDEP,70,86,88 animal models carrying loss-of-function 
variants exhibit milder seizure phenotype.71,72 In addition, Kcna1 SUDEP model crossed 
with a Cacna1a absence seizure mouse has mild seizure phenotype and improved survival.89 
Furthermore, modulation of neuronal hyperexcitability and premature mortality extends 
beyond genetic interactions of the ion channel network; the deficiency of the microtubule-
binding protein tau in the Kcna1 knockout mouse not only reduced the seizure frequency 
and severity, but also improved survival.90 A human example of genomic complexity in 
SUDEP was recently illustrated by a pediatric case with DS, frequent ictal apnea, and 
suspected cardiac arrhythmias.52 Detailed genomic analysis uncovered interesting 
combinations of SNPs and copy number variants in genes expressed in both neurocardiac 
and respiratory control pathways, including SCN1A, KCNA1, RYR3, and HTR2C.
Understanding SUDEP Genetics in Populations—The Australian Experience
Tu et al.38,50 carried out a retrospective review of postmortem reports performed at a single 
forensic center between 1993 and 2009, identifying 68 cases: the cause of death was 
“SUDEP” or “possible SUDEP” in 22 and 46 cases, respectively. Postmortem blood was 
available in 48 cases, and DNA was screened for variants in the most common LQTS 
genes,38 KCNQ1, KCNH2, and SCN5A, as well in the HCN gene family.43,44,50 There was 
a KCNH2 Arg176Trp and Arg1047Leu missense variation in one and four SUDEP cases, 
respectively, a single Ala572Asp, Pro1090Leu, and Pro2006Ala missense variation in 
SCN5A in three SUDEP cases38 and nine nonsynonymous HCN genic variants.50
The Arg176Trp variant in KCNH2 is a nonconservative substitution in a highly conserved 
N-terminal region of the protein. According to bioinformatic (in silico) analysis, it is 
probably damaging. The KCNH2 176Trp allele is a common founder mutation associated 
with a prolonged QT interval in Finnish LQTS families.91–93 It is also reported in a case of 
sudden unexplained death.94 In vitro functional studies have shown that the Arg176Trp 
substitution alters ion channel function, causing accelerated channel deactivation and 
reduced potassium current density, resulting in a prolonged QT interval.92 Collectively, these 
results implicate the KCNH2 Arg176Trp variant in prolongation of the QT interval, a likely 
trigger of a fatal arrhythmia in the SUDEP case, a 35-year-old man, reportedly diagnosed 
with epilepsy 5 years prior to death who had 10 episodes requiring hospitalization; 
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neuropathology examination reported left hippocampal sclerosis. KCNH2 Arg1047Leu is a 
common variant found in 2.9% SUDEP cases (2.9%). One patient with SUDEP, a 52-year-
old woman with a history of controlled epilepsy, carried the KCNH2 Arg1047Leu 
polymorphism in addition to the rare SCN5A Ala572Asp variant that has been reported 
previously in LQTS and in a case of sudden cardiac death.95,96 Neuropathology reported 
microdysgenesis in the left hippocampus. As discussed earlier,7 it is plausible that the 
combined effect of these two protein-changing variants raised the risk of sudden death in 
this patient. SCN5A Pro2006Ala is a rare variant with a minor allele frequency (MAF) of 
0.1%, reported previously in a case of unexplained cardiac arrest and LQTS.97,98 This 
variant was found in a 43-year-old man who died of SUDEP who had nocturnal seizures. 
The SCN5A Pro1090Leu variation shows ethnically variable MAF of 0.008% in European 
and African ancestry but 2% in an Asian subpopulation. It is considered an Asian-specific 
polymorphism.99,100 This variant was found in a 23-year-old from China with a history of 
poorly controlled epilepsy. HCN2 Phe738Cys is a nonconservative substitution in the 
carboxyl-cytoplasmic tail of the HCN2 protein, predicted by in silico to be possibly 
damaging. It was detected in a 52-year-old man, a carrier of the common KCNH2 
Arg1047Leu polymorphism. The patient had infrequent seizures since the age of 16 years. 
HCN2 Pro802Ser is a nonconservative substitution in the carboxyl-cytoplasmic tail, 
predicted to be benign. It was detected in a 43-year-old man, also a carrier of the SCN5A 
Pro2006Ala variant, and who had a witnessed nocturnal seizure. HCN4 Gly973Arg is a 
nonconservative substitution found in a 44-year-old man with reportedly regular seizures 
prior to death.
Genetic analysis of the Australian SUDEP cohort supports the hypothesis that genes 
encoding K+, Na+, and Ca2+ ion channels expressed both in neuronal and/or cardiac cells are 
likely to play an important role in the predisposition of epilepsy patients to SUDEP.38,50 It 
remains to be determined whether these ion channel variants are the genetic cause in some 
SUDEP cases or an accompanying risk factor in the sudden death of patients with epilepsy. 
The variants may act in isolation or require the presence of a second genetic factor or 
environmental influence, such as uncontrolled seizures, QT-prolonging AEDs, or 
noncompliance with AED therapy, to predispose epilepsy patients to malignant arrhythmias 
and sudden death. Screening candidate genes, one at a time, limits the scope of genetic 
studies. Furthermore, although postmortem blood offers an ideal source of DNA for genetic 
studies in SUDEP, it is of finite supply, and not always available. Recent major advances in 
DNA enrichment and “next-generation” sequencing technologies have provided a new and 
powerful approach to identify mutations responsible for genetic disorders. The ability to 
enrich and sequence all of the protein coding exons (the exome) reduces the target region to 
1.5% of the genome, while retaining the sequences most likely to harbor the majority of 
variations with high penetrance.101
Genetics of SUDEP: Tissue Collection and Utilization
Genetic variation likely contributes to SUDEP risk, but it is unclear how such variation 
might best be identified; in particular what samples are needed, what methods and analyses 
might be used, and how potential genetic leads might be followed through.
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DNA collection for genetic studies in epilepsy is well established. Worldwide, tens of 
thousands of DNA samples have now been collected, and many thousands genotyped102 or 
exome sequenced. The genetic study of SUDEP clearly provides a different level of 
challenge, as SUDEP cannot be predicted and there is no “target” population, although some 
groups of patients might be considered at greater risk. Collection in life for SUDEP studies 
is challenging, although greater SUDEP awareness103 could facilitate this. Collection after 
SUDEP is difficult to systematize. The logistic difficulties of obtaining postmortem material 
require an awareness of the need and the processes, appropriate consent, and an established 
infrastructure. Up until now, most genetic studies of SUDEP have been of single cases or 
small series. In view of this, Klassen et al.104 investigated the possibility of using other 
sources for DNA in SUDEP. They were able to extract DNA that could be used for at least 
some studies from blood spots on Guthrie cards, buccal scrapes on Guthrie cards, and from 
fingernails. In the field of oncology, it is now a well-established practice to undertake 
candidate gene or genome-wide whole exome sequencing from formalin-fixed paraffin-
embedded samples, including brain. This has opened up large archival collections for 
research.
Advancing technology now allows for genetic studies using ever-smaller samples of DNA. A 
recent pathologic study of 143 archived brain samples105 established the potential of this 
approach which in future could use prospectively collected samples from both postmortem 
and surgical cases, SUDEP and otherwise, to generate a regulated and approved resource for 
further research into, among other areas, SUDEP.
Clinical Implications
It is difficult at this time to translate genetic advances into pragmatic advice for patients, 
particularly as SUDEP tragically affects a wide range of individuals with epilepsy. Indeed 
there may be distinct separate populations at risk of SUDEP, with potentially different 
mechanisms. One group of individuals, typically young adults, with no significant prior 
known comorbidities and infrequent seizures, who die suddenly might represent a different 
population from those with severe epilepsy who manifest with frequent generalized 
convulsions. In the former group, genetic susceptibility to epilepsy may be associated with a 
genetic susceptibility to sudden cardiac death.106 In the latter group, there may be complex 
additive interactions between polygenetic factors, medication, and the consequences of 
frequent severe seizures. In SUDEP, there is currently no evidence to guide practice for 
routine genetic testing. However, with genetic screening for long-QT–associated mutations, 
once confined to the research laboratory, now clinically available as diagnostic tests,107 any 
SUDEP case should have a careful review of the family history, and any concern should 
result in a molecular genetics study.
The first priority in epilepsy practice is to ensure that patients do have epilepsy, rather than a 
cardiac disorder.108 All new epilepsy patients must undergo a careful cardiac history and a 
detailed family history, particularly asking about sudden cardiac death and unexplained 
deaths in infancy. All patients, indeed anyone who has a blackout, should have an 
electrocardiogram (Table 1). Modern automated ECG machines may help screen for cardiac 
disorders, but a cardiologist, experienced in the relevant abnormalities, must review any 
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abnormalities identified as potentially abnormal. Epilepsy patients with an abnormal or 
equivocal ECG study, or any suspicious family history, should undergo specialist cardiac 
review. A specialist cardiac review should also be arranged for any patients who report 
suspicious symptoms including exercise-related seizures, or where there is witnessed 
profound pallor during seizures. Such patients should be assessed for possible prolonged 
monitoring, ideally with an implantable event recorder (IER) (Table 1). It is likely that at 
present barriers to arranging such specialist assessments result more from lack of awareness 
among neurologists rather than from resistance from cardiology services.
Even in expert hands, however, spotting QT abnormalities is problematic, most cardiologists 
miss them,109 and IER is costly.110 It is important that all those who care for people with 
epilepsy be aware that not only might potentially life-threatening cardiac disorders mimic 
epilepsy,111 but also patients with epilepsy might be at increased risk of concurrent cardiac 
arrhythmias.
Developing the hypothesis that there might be (at least) two distinct populations within 
SUDEP cases, and considering those with frequent generalized seizures despite medication, 
the use of IER technology needs to be assessed looking for potential markers of cardiac 
instability. It has long been recognized that some patients have identifiable cardiac 
abnormalities in the interictal state,112 and during seizures,113,114 including varying degrees 
and types of heart block. In addition, such patients may have disturbances of autonomic 
function, both when untreated,115 and also possibly associated with treatment116; 
withdrawal of treatment may exacerbate these abnormalities.117 These interictal and ictal 
cardiac disturbances might be of particular significance in those with severe medically 
intractable epilepsies, and in this group, therefore, the results of prolonged cardiac 
monitoring might be used to guide drug choices, including nonepilepsy drugs, could help 
with counseling about other potentially modifiable risk factors, and might result in 
implantable devices to protect selected patients.113
These proposals represent significant changes to current routine practice, and require an 
increased awareness of the risks of SUDEP for patients. Highlighting these risks to patients 
has implications.103 Furthermore, the proposals require increased engagement among 
neurologists regarding the need for review of cardiac risk factors. An informal survey of 
United Kingdom cardiac electrophysiologists by one of the authors (PC) suggests that 
cardiologists already acknowledge the need to investigate such patients. Many young adults 
who die of SUDEP are not dissimilar to young adults who die of SCD. Increased public 
awareness of SCD has improved its prevention. It is hoped that increased public awareness 
of the risks of epilepsy might do the same for SUDEP.
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Key Points
• Evidence suggests likely genomic complexity and a degree of overlap 
among among sudden cardiac death, sudden infant death syndrome, 
and SUDEP
• In some genetic epilepsies, a mutation may also predispose to sudden 
death, whereas in acquired epilepsies, coexisting genetic variants may 
increase susceptibility
• For patients with epilepsy, a cardiac history and an electrocardiogram 
should be obtained, as well as a careful family history for sudden or 
unexplained deaths
• Awareness that life-threatening cardiac disorders can mimic epilepsy 
and that patients with epilepsy might be at increased risk of cardiac 
arrhythmias is needed
• Many challenges remain, and future progress requires collaborative 
transdisciplinary research
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Table 1
Suggested minimum cardiac assessment for individuals with seizures
All patients
 ECG with computer analysis
 Careful history of events, specifically questioning cardiac features
  Exercise-related events
  Reported profound pallor at time of seizures
  Family history for
  Sudden unexplained, or established cardiac deaths, especially <40 years age
  Sudden infant death syndrome (SIDS)
  Relative with SUDEP
If any of the above, including any uncertainty
 Consider ECG studies of first-degree relatives, with computer analysis
 Formal specialist cardiology assessment
  Consider exercise ECG and/or pharmacologic provocation
  Consider implantable event recorder
 Consider genetic referral for molecular genetics study including family members
Epilepsia. Author manuscript; available in PMC 2016 September 23.
